Quantcast

Latest biopharmaceutical Stories

2014-06-18 08:28:25

BASKING RIDGE, N.J., June 18, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (also known as REG1), its first-in-class, actively controllable injectable antithrombotic drug system, today announced the appointment of Drew Fromkin to the company's Board of Directors. Mr. Fromkin most recently served as President, Chief Executive Officer, of Clinical Data, Inc., prior to its...

2014-06-17 08:29:28

LA JOLLA, Calif., June 17, 2014 /PRNewswire/ -- Avidity NanoMedicines, a biopharmaceutical company pioneering development of the Antibody-siRNA Complex (ARC(TM)) as a new therapeutic class, announced today the issuance of two new U.S. patents. ARCs(TM) combine the potency and specificity of biologics with a nucleic acid-based payload, representing a breakthrough approach to the targeted delivery of nucleic acid-based medicines. The two new U.S. patents arose out of pioneering work...

2014-06-17 08:28:44

SEATTLE, June 17, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into a Master Services Agreement for process validation activities and clinical manufacturing of another of MacroGenics'...

2014-06-12 08:29:12

Company Must Remedy Noncompliance with Audit Committee Requirements as Set Forth in Listing Rule 5605 HERZLIYA, Israel, June 12, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that it received a letter from the Nasdaq Stock Market LLC ("Nasdaq") dated...

2014-06-12 08:28:46

SAN DIEGO, June 12, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced two poster presentations at the 19(th) Congress of the European Hematology Association (EHA), to be held June 12 through June 15, 2014, in Milan, Italy. Quizartinib (AC220) in Patients with FLT3-ITD(+) Relapsed or Refractory Acute Myeloid Leukemia: Final...

2014-06-12 08:28:27

Today most medicines are produced biotechnologically. A new cleaning method developed at ACIB combines five purification steps and leads to an extremely facilitated, more economical and ecological manufacturing process. GRAZ, Austria, June 12, 2014 /PRNewswire/ -- Seven of the ten best-selling drugs in 2012 were biopharmaceuticals; biotechnology in pharmaceutical production is still growing. A severe problem is the cleaning of products; up to 80% of the total production costs are...

2014-06-10 08:29:48

QUÉBEC CITY, June 10, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources...

2014-06-09 16:25:42

JUPITER, Fla., June 9, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced that Dyadic's Chief Operating Officer Danai Brooks will present at the 2014 Global Biotechnology Conference on Wednesday, June 18, 2014 at 4:10 p.m. ET at the John B. Hynes...

2014-06-05 23:09:14

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing Geneva, Switzerland (PRWEB) June 05, 2014 Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One...

2014-06-04 08:30:14

SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce the distribution of a letter from Hojabr Alimi, the Company's Chairman, Chief Executive Officer and Chief Science Officer, to its stockholders on Form 8-K on June 3, 2014. A download of the full PDF of this...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.